cover image European Journal of Neurology

European Journal of Neurology

1998 - Volume 5
Issue 3 | May 1998

Review

Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) can be considered as a new disease predominantly affecting the small vessels of the brain with an autosomal dominant transmission linked to chromosome 19. This review includes an historical perspective showing how the disease was identified from the spectrum of vascular leukoencephalopathies. More than two hundred patients have now been described, belonging to at least 30 unrelated pedigrees in Europe, America and Asia. The clinical features include four major neurological presentations associated in variable degrees during the course of the disease: migraine with or without aura, strokes or stroke‐like episodes, major psychiatric symptoms and dementia. The patients are free of the classical vascular risk factors. The disease has a progressive or stepwise course with age at onset in the forties and a mean duration of 13.6 I 10.7 years. Death occurs in the fifties in a characteristic condition associating a pseudo‐bulbar syndrome and subcortical dementia. Cerebral magnetic resonance imaging (MRI) is highly contributive to the diagnosis, showing a diffuse leukoencephalopathy with subcortical infarcts in the basal ganglia and white matter. Pathological data show macroscopic lesions similar to Binswanger's disease but different lesions of the small vessels including thickening of the media, characteristic PAS+ granular material and narrowing of the lumen. Skin biopsy may be a valuable diagnostic tool, showing ultrastructural alterations of skin vessels similar to those of brain vessels. The disease is highly homogeneous on a genetic basis and the identification of the gene Notch 3 on chromosome 19 has opened new avenues for research and genetic counselling. The pathogenesis of the disease has still to be elucidated. A definite diagnosis relies on genetical or pathological data. Diagnostic criteria are proposed to recognize the disease on clinical and imaging parameters. So far, no treatment has been reported to be successful for CADASIL.

Research Papers

Abstract

Pramipexole (SND 919), a potent non‐ergot dopamine agonist, or placebo, was administered to 69 patients with advanced Parkinson's disease (33 received placebo, 36 received pramipexole) in a double‐blind, randomized, multi‐center study in which individually optimized doses of ‐dopa plus a dopa decarboxylase inhibitor were associated with dyskinesia, “on–off” fluctuation, dystonia, akinesia, or end‐of‐dose deterioration. Study medication was titrated over 7 weeks to the maximal tolerated dose or to the maximal dose allowed by the study (5 mg/day in four divided doses). Dosing was maintained for 4 weeks and then tapered during the final week. Total score on the Unified Parkinson's Disease Rating Scale (UPDRS) for the intent‐to‐treat population was significantly improved in the pramipexole‐treated group compared with the placebo‐treated group (16.9 ± 14.9 vs 9.0 ± 16.1; = 0.0184). By the end of maintenance, the mean reduction in ‐dopa requirement was −150.7 mg for pramipexole‐treated patients compared to −10.6 for placebo‐treated patients. The most common adverse events (> 10%) were dizziness, insomnia, nausea, and postural hypotension. Aggravated parkinsonism occurred only after withdrawal of the study medication. Treatment with pramipexole in doses up to 5 mg/day was safe and well tolerated by patients with advanced Parkinson's disease.

Research Papers

Abstract

We studied pre‐synaptic and post‐synaptic function in the striatum of a patient with juvenile parkinsonism (JP) using positron emission tomography (PET). [F]6‐fluorodopa (FDOPA), C‐YM‐09151‐2 and [F]fluoro‐2‐deoxy‐‐glucose (FDG) were used to measure fluorodopa uptake, dopamine D receptor binding and glucose metabolism, respectively. In this patient, FDOPA accumulation was decreased markedly in the caudate nucleus and the putamen bilaterally. In the images of C‐YM‐09151‐2 and FDG in contrast, no conspicuous changes were observed in the striatum. Thus our PET studies using FDOPA, C‐YM‐09151‐2 and FDG provide a useful approach for assisting the diagnosis of JP, because the present findings are different from the results in patients with dopa‐responsive dystonia and hereditary progressive dystonia with marked diurnal fluctuation. Furthermore, our findings are of particular interest in relation to the pathogenesis of JP.

Research Papers

Abstract

We report a preliminary pilot study on the clinical efficacy of flunarizine (FNZ), a calcium‐entry blocker that causes extrapyramidal side‐effects, in 10 patients with Huntington's disease (HD). FNZ (20 mg) administered by the sublingual route resulted in a decrease in choreic movements and improved dexterity in performing several tests. These effects lasted for at least 7 days after a single dose. Therefore, FNZ seems to exert the same effect as a long‐acting neuroleptic agent in our HD patients.

Research Papers

Abstract

Levodopa‐carbidopa (LD) in low dosages adequately controls symptoms in most patients with Parkinson's disease and delays the appearance of fluctuations and dyskinesias. It has been suggested that early combination therapy with bromocriptine and levodopa delays or prevents the onset of late treatment complication associated with LD monotherapy in Parkinson's disease. We have conducted this study to assess the possible benefit of combined therapy compared with levodopa monotherapy. Seventy‐eight previously untreated patients with Parkinson's disease were recruited over a period of 54 months and randomly allocated to either a levodopa‐carbidopa (LD) Group or a levodopa‐carbidopa in combination with low‐dose bromocriptine (LD‐Br) Group. The appearance of motor complications determined the end point of the study. We gradually increased the doses of bromocriptine (2.5–15 mg/d) or levodopa (125–500 mg/d) until the maximum “on” time was reached. In six patients, the doses of levodopa had to be increased up to the optimal dose (625–1000 mg/day). In the last evaluation the on‐time and parkinsonian disability were similar in both treatment groups. We did not find statistically significant differences in the frequency of motor complications when comparing the two groups of treatment. Our study suggests that early combination of levodopa and bromocriptine does not confer any clinical benefit over levodopa alone in treating early Parkinson's disease, nor will it influence the evolution of the disease.

Research Papers

Abstract

Inflammatory cell infiltration within the central nervous system (CNS) and upregulation of both pro‐ and anti‐inflammatory cytokines are characteristic for multiple sclerosis (MS). Treatment with interferon‐β1b (IFN‐β1b) reduces the number and severity of MS relapses. To examine whether treatment with IFN‐β1b affects levels of cytokine mRNA expressing blood mononuclear cells (MNC) we employed in‐sit hybridization with synthetic oligonucleotide probes to detect and enumerate IFN‐γ, TNF‐α, IL‐10, TGF‐β and perforin mRNA expressing cells in MS patients before treatment with IFN‐β1b and during tretmetn for 3–6 weeks and for 3–6 monts. Numbers of blood MNC spontaneously expressing TNF‐α and IL‐10 mRNA were lower after 3–6 months of treatment, while numbers of IFN‐γ, TGF‐β and perforin mRNA expressing MNC were not affected by treatment. IFN‐β1b had no influence on levels of MBP‐reactive IFN‐γ, TNF‐α, TGF‐β, IL‐10 or perforin mRNA expressing blood MNC determined after 3–6 weeks 3–6 months of treatment. Parallel measurements of plasma concentrations of soluble vascular cell adhesion molecule‐1 (sVCAM‐1) revealed elevated levels after 3–6 weeks of treatment and these levels remained higher after 3–6 months of treatment. The results suggest that IFN‐β1b treatment upregulates plasma levels of sVCAM‐1, but has little effects on numbers of blood MNC expressing mRNA of the pro‐ and anti‐inflammatory cytokines under study.

Research Papers

Abstract

Serotonin (5‐HT) plays a major role in the pathophysiology of primary headaches. The presynaptic 5‐HT uptake mechanism, which is important for the regulation of 5‐HT levels in the neuronal synapses, can be examined indirectly by measuring the number of 5‐HT transporters in membranes from platelets. The aim of the present study was to investigate the platelet 5‐HT transport system in patients with primary headache disorders. , an index of the number of platelet 5‐HT transporters, was measured in 40 patients with chronic tension‐type headache, in 30 patients with migraine without aura, and in 40 healthy controls using a binding analysis with tritiated paroxetine as the ligand. The was 664 (589–846) (median (quartiles)) fmol/mg protein in patients with tension‐type headache and 662 (534–781) fmol/mg protein in healthy controls, = 0.40. The was 675 (558–747) fmol/mg protein in patients with migraine, which was not significantly different from the in controls, = 0.94. In conclusion, the present results indicate that the number of platelet 5‐HT transporters is normal in patients with chronic tension‐type headache and in patients with migraine without aura.

Research Papers

Abstract

Cognitive impairment is a frequent feature in multiple sclerosis patients. To assess its evolution in comparison with clinical and neuroradiological evolution, we followed up 57 multiple sclerosis patients over a 3‐year period. During this time EDSS deteriorated significantly but not the MRI lesional load nor the cognitive test performance; nevertheless both at the beginning and at the end of the follow‐up neuropsychological results showed a significant correlation with both EDSS and lesional load. No clinical or paraclinical features could reliably predict neuropsychological evolution.

Research Papers

Abstract

Lupus anticoagulant (LA), IgG and IgM isotypes of anticardiolipins (aCL), lipoprotein (a), and the resistance to activated protein C were determined in patients with ischemic stroke. The raised concentration of the aCL‐IgM isotype was noted in 42% of patients with this type of stroke, and it was in contrast with an 8% frequency of an increased level of aCL‐IgG isotype in these cases. The high level of lipoprotein (a) was found with similar frequency in stroke patients and in age‐matched control subjects. It is concluded that the elevated concentration of IgM isotype of anticardiolipin antibodies can be regarded as significant in the ethiological work‐up in elderly stroke patients.

Short Report

Abstract

Disorders of learning and memory are a frequent finding in nondemented Parkinson disease (PD) patients. It is not clear to what extent depression, present in at least half the cases of PD, contributes to these disorders. This paper investigates the possible influence of depression on tests of episodic memory in patients with Parkinson's disease (PD). We studied three groups of 11 subjects each (controls, non‐depressed PD, mildly to moderately depressed PD). Neuropsychological tests included tests of short and long‐term memory in verbal and non‐verbal modalities. The two groups of PD patients performed significantly worse than controls on the memory tests, but there were no differences between the depressed and non‐depressed PD patients. This lack of influence of depression on neuropsychological performance is compatible with Starkstein's view that cognitive imnpairment is only found beyond a given threshold of depression severity.

Short Report

Abstract

We examined the usefulness of methylphenidate (MPH) in the treatment of organic amnesia in a randomized, double‐blind, placebo‐controlled design. Twenty patients with amnesia due to closed head injuries (= 10), viral encephalitis (= 2), stroke lesions (= 4), or surgical brain resections (= 4) were assessed with a neuropsychological battery after the intake of MPH (10, 20, 30 or 40 mg), or placebo. We found no significant benefit of MPH for any of the cognitive tests.

Case Report

Abstract

We report a case of increase in seizure frequency and severity in a 26‐year‐old woman receiving folic acid at a dosage of 0.8 mg/day. She had symptomatic partial epilepsy with simple and complex seizures treated with carbamazepine. She was planning pregnancy and we prescribed folic acid for prevention of neural‐tube defects. In the next few days she had a generalized tonic–clonic seizure for the first time and a significant increase in seizure frequency. Because of the temporal relation between the seizure worsening and the administration of folk acid, we hypothesize a role of folic acid in provoking seizures, as has been reported in the literature.

Case Report

Abstract

Facial nerve palsy is the commonest cranial neuropathy affecting 40/100 000 people in the Western World but is idiopathic in 50–70% of cases. This report describes a case of recurrent facial nerve palsy in association with herpes simplex virus (HSV) reactivation. HSV may be a major cause of racial nerve palsy. Further research is required to clarify this issue in order that targeted treatment strategies can be developed for this common problem.

Case Report

Abstract

A young male patient who presented with steroid‐responsive parkinsonism, hemiplegia, thrombocytopaenia and systemic illness who was subsequently diagnosed to have systemic lupus erythematosus (SLE) is described. He later developed post‐hemiplegic dystonia. Thalamic lesions on magnetic resonance imaging (MRI) are demonstrated. Clinical features and neuropathology of central nervous system lupus are discussed. This is the first report of SLE presenting with Parkinsonism, and the first to demonstrate anatomically‐relevant MRI lesions in Parkinsonism associated with SLE.

Letters to the Editor

Association between type II adult glycogenosis inflammatory polyneuropathy and hypophyseal adenoma: a case report

Letters to the Editor

Treatment for steroid‐induced diabetes with α‐glucosidase inhibitor, voglibose

Letters to the Editor

Pediatric bilateral carpal tunnel syndrome as first manifestation of hereditary neuropathy with liability to pressure palsies (HNPP)

Book Reviews

Behavioral neurology and the legacy of Norman Geschwind

Book Reviews

New therapeutic implications of antidepressants

Book Reviews

Cognitive rehabilitation for neuropsychiatric disorders

Book Reviews

Long‐term treatments of anxiety disorders

Book Reviews

Handbook of neuropsychology

Book Reviews

Syncope: mechanisms and management

Book Reviews

Frontiers in cerebrovascular disease. Mechanisms, diagnosis, and treatment